Kathryn A. Whitehead

Dr. Kathryn A. Whitehead is a Professor in the Department of Chemical Engineering and holds a courtesy appointment in the Department of Biomedical Engineering at Carnegie Mellon University. She joined the faculty in 2012 after completing postdoctoral training at MIT. Her research focuses on engineering drug delivery systems for RNA therapeutics, maternal-infant health, and overcoming biological barriers to enhance drug efficacy. Key areas include lipid nanoparticle (LNP) design for mRNA delivery, intestinal permeation enhancement, and leveraging maternal milk cells for therapeutic applications.

Education: H.B.Ch.E., University of Delaware (2002); Ph.D., University of California, Santa Barbara (2007); Postdoctoral Fellow, MIT (2008–2012).

Research Interests: Drug delivery systems, RNA interference, bionanotechnology, personalized medicine, and translational nanomedicine for diseases such as cancer and diabetes. Her lab develops novel LNPs for targeted delivery to tissues like the liver, brain, and pancreas.

Awards and Recognition: AIMBE Fellow, DARPA Young Faculty Award (2016), CMBE Young Innovator Award (2016), MIT Technology Review Innovator Under 35 (2014), and NIH Director’s New Innovator Award. Her work has been cited over 9,000 times, with patents in RNA delivery and permeation enhancers.

Lab Members: Active researchers include Ph.D. students, postdocs, and undergraduates working on projects such as LNP formulation, maternal milk cell biology, and siRNA therapies. Notable alumni have advanced to roles at Moderna Therapeutics, Verve Therapeutics, and academic institutions.

Grants and Funding: Supported by NIH, DARPA, and industry partnerships. Current projects include NIH grants on pregnancy-safe mRNA delivery and DARPA funding for maternal-infant therapeutics.